![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Karger
E-ISSN: 1421-9794|58|1|60-69
ISSN: 0009-3157
Source: Chemotherapy, Vol.58, Iss.1, 2012-02, pp. : 60-69
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Efficacy of Docetaxel as a Second-Line Chemotherapy for Thymic Carcinoma
Chemotherapy, Vol. 50, Iss. 6, 2004-12 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
A Phase II Study of Docetaxel and Oxaliplatin for Second-Line Treatment of Urothelial Carcinoma
Chemotherapy, Vol. 55, Iss. 5, 2009-07 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)